Zurich-Schlieren, Switzerland, April 4th, 2023. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today announced that Pascal Brenneisen has been appointed Chief Executive Officer (CEO),effective April 1, 2023, on top of his Board member assignment. He will succeed Reto Naef, who will concentrate as President on the company strategy and mid-term on the preparation for an IPO. During the transition he will support the new CEO and take over the role of as Chief Operating Officer (COO).
Pascal Brenneisen is an entrepreneurial, strategic, and commercial leader with over 30 years of experience building businesses and delivering sustainable results across Europe and Asia pharmaceutical and healthcare value chains. Previously, he held leadership positions as General Manager and Regional Head in the biopharmaceutical industry and served as a Board member and co-founder of several emerging companies. He holds a master’s degree in law from the University of Basel and accomplished several Executive Educations at Harvard, Stanford and IMD.
Mr. Brenneisen said, “I’m very excited to take on this operational role and building upon my experiences within TOPADUR as a Board member since 2015. TOPADUR made great progress in developing disruptive therapies to treat high unmet medical needs thanks to a competent and dynamic team. I look forward to supporting TOPADUR in the next chapter for an IPO”.
“I am very pleased that we are appointing Pascal Brenneisen as TOPADUR’s new CEO, who has broad and international experience in the healthcare industry and a deep understanding of our business”,says Reto Naef, Chairman of the Board of Directors of TOPADUR Pharma AG. “I know Pascal since many years and we worked successfully together in the past. I’m convinced that we strengthen the company significantly and together with Pascal, TOPADUR has a strong and very complementary leadership team that will take the company to the next level and increase the chances for success. I will mainly focus on long term aspects and in addition support Pascal in the coming months as COO.”
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.Read more
EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.Read more